TrueRepertoire Sequencing Service

The currentin vitroscreening method for antibody discovery selects clones at random, then proceeds with an assay, leading to a high chance of repeated discovery of the same antibody existing in large quantities as well as a low chance of finding antibodies with various characteristics and binding capacities existing at low frequencies.

In contrast, switchingin vitroscreening and DNA sequence analysis steps enables confirming the antibody sequences in the library and checking their binding capacities without repeatedly discovering identical antibodies. This has allowed our clients to obtain increased number of clones with confirmed binding capacities in the most cost-effective way compared to conventional methods. With TrueRepertoire™, our clients can discover rare clones that have not been detected previously with drastically reduced time and cost.

Provision of antibody DNA sequence library containing over 10,000 errorless strains

• NGS-based sequence analysis, high-capacity clone separation, molecular barcode assays using Celemics proprietary MSSIC technology

Provision of physical property analysis of each antibody through bioinformatics analysis

• Clone frequency distribution within the library, VH and VL sequence length distribution, post-translation modification information, CDR and frame amino acid information, etc.

VH-VL Linkage analysis of each antibody

• Provision of VH-VL Linkage information, an area previously difficult to analyze through NGS due to its short read length

Retrieval of selected physical antibody

• When using existing technologies to run NGS-based antibody sequence analysis, it is possible to obtain the sequence but impossible to get DNA material for each clone, requiring a costly gene synthesis process.
• Celemics’ TrueRepertoire™ Antibody Sequencing Service contains the client’s desired antibody clone within the library itself, eliminating the need to perform new gene synthesis and decreasing the required time and cost.